Jeffrey Weitzel, MD, FACMG

Articles by Jeffrey Weitzel, MD, FACMG

Evaluating HRR and MMR in Advanced Prostate Cancer: © Sebastian Kaulitzki - stock.adobe.com

Homologous Recombination and Mismatch Repair Assessment in Men With Advanced Prostate Cancer: A Cross-Sectional Study From a Center in Mexico City

ByJosé Luis Rodríguez-Olivares, MD,Mauricio Mora Pineda, MD,Evelyn Beas-Lozano, MD,Alec Seidman-Sorsby, MD,Yuly A. Remolina-Bonilla, MD, MSc,Armando Gamboa-Domínguez, MD,Jeffrey Weitzel, MD, FACMG,Pedro Barata, MD, MSc,Yanin Chavarri-Guerra, MD, MSc, FASCO,María T. Bourlon, MD, MSc, FASCO

July 22nd 2026

This cross-sectional study evaluated the genetic landscape of a cohort of patients with metastatic prostate cancer who were treated at a referral center in Mexico City, Mexico.

Breast Cancer Overview: Risk Factors, Screening, Genetic Testing, and Prevention

ByLori Jardines, MD,Sharad Goyal, MD,Paul Fisher, MD,Jeffrey Weitzel, MD, FACMG,Melanie Royce, MD, PhD,Shari B. Goldfarb, MD

June 1st 2015

This management guide covers the risk factors, symptoms, screening, diagnosis, prevention, and staging of breast cancer.

Jeffrey Weitzel, MD, FACMG

Articles by Jeffrey Weitzel, MD, FACMG

Homologous Recombination and Mismatch Repair Assessment in Men With Advanced Prostate Cancer: A Cross-Sectional Study From a Center in Mexico City

Breast Cancer Overview: Risk Factors, Screening, Genetic Testing, and Prevention

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Camizestrant for ESR1-Mutated HR+/HER2– Advanced Breast Cancer

Novel Agent Earns FDA Breakthrough Therapy Designation for HPV+ Oropharyngeal Cancer

Debating Camizestrant, ctDNA Monitoring, and SERENA-6 in HR+ Breast Cancer

Saturated Fat Intake Linked to Greater Mortality in Nonmetastatic Prostate Cancer

How Do Final CAPItello-291 OS Data Shape Capivasertib Use in Breast Cancer?